Skip to main content
Zyvex Zyvex Pharmaceuticals
Photo 1 of 1 Click to zoom

Product photograph of the current pack. Each physical unit carries the same blue-teal ZX label artwork, a batch code and a scratch-off verification panel.

Selective Androgen Receptor Modulators

Ibutamoren (MK 677)

Ibutamoren

Compound
Ibutamoren
Brand
Ibutamoren
Manufacturer
Zyvex Pharmaceuticals
Presentation
100 tabs
Strength
25 mg/tab
Route
Oral
Storage
15–25 °C, protected from light, do not freeze

Batch analysis

Independent batch results for Ibutamoren (MK 677) are not yet published. They will be added here once testing is complete.

Product information

About Ibutamoren (MK 677)

25 mg per tablet · 100 tablets · Zyvex Pharmaceuticals

Ibutamoren (MK 677) from Zyvex Pharmaceuticals contains ibutamoren at 25 mg per tablet and comes in a pack of 100 tablets.

This prospect summarises composition, clinical considerations and handling. It supports professional review and does not replace an individual prescription or verified instructions for the exact preparation.

Basic Identification & Composition

Product Name & Active Ingredient

Ibutamoren (MK 677) is the product name used by Zyvex Pharmaceuticals. The ingredient discussed in the following sections is ibutamoren, classified as a ghrelin-receptor agonist and growth-hormone secretagogue.

Qualitative & Quantitative Composition

Property Details
Product name Ibutamoren (MK 677)
Manufacturer Zyvex Pharmaceuticals
Active ingredient Ibutamoren
Strength 25 mg per tablet
Package 100 tablets
Drug class Ghrelin-receptor agonist and growth-hormone secretagogue
Chemical formula C27H36N4O5S (free base)
Dosage form and route Tablet; oral

Dosage Form

A solid tablet for oral administration. Each tablet provides a measured amount of active ingredient. Confirm suitability with a pharmacist before splitting or crushing; appearance and score lines alone do not establish accurate dose division.

Clinical Particulars

Ibutamoren (MK 677) uses

Ibutamoren (MK 677) from Zyvex Pharmaceuticals contains ibutamoren. Ibutamoren stimulates growth-hormone secretion and has been studied for age-related changes in body composition. Research on fat-free mass does not by itself demonstrate treatment of frailty or improved daily function.

People seek ibutamoren for muscle gain, appetite and perceived recovery or anti-ageing effects. These goals should be distinguished from measured clinical benefits.

A controlled trial in adults aged 60–81 used 25 mg orally once daily, with primary outcomes after one year. Fat-free mass increased, but strength and function did not improve; glucose and insulin-sensitivity changes also occurred. This research schedule does not establish a safe bodybuilding or wellbeing protocol.

Dosage and Administration

A reliable routine human dosing regimen cannot be established from the available clinical evidence. The product strength must not be converted into a self-treatment schedule. Human use requires an appropriately supervised clinical or research setting with a defined protocol. A 25 mg research dose appearing in a trial does not establish that this tablet is appropriate for unsupervised treatment.

Contraindications

A complete clinical contraindication profile has not been established. Avoid exposure with known hypersensitivity, during pregnancy or breastfeeding, and in children outside a properly reviewed clinical setting. Absence of a listed contraindication is not evidence of safety. Diabetes, impaired glucose tolerance, oedema and heart failure warrant particular clinical attention.

Warnings and Precautions

Ibutamoren can increase glucose and reduce insulin sensitivity. Fluid retention is a concern; heart-failure risk has been raised in clinical safety reviews. Review fasting glucose, symptoms of swelling and cardiometabolic history before any research exposure.

Risks and Interactions

Drug & Food Interactions

Human interaction studies are limited. A clinician or study team should review all prescription medicines, nonprescription products and supplements. There is no basis for assuming that combinations with other experimental compounds are safe. Medicines for diabetes and other agents affecting growth-hormone signalling deserve specific review.

Pregnancy and Lactation

Adequate pregnancy, lactation and reproductive safety evidence is lacking. Avoid exposure during pregnancy or breastfeeding. Any reproductive-risk precautions in a clinical study should be directed by the study team.

Side Effects and Adverse Reactions

Trials have reported increased appetite, lower-limb swelling and muscle pain, alongside changes in glucose regulation. Improvement in a laboratory hormone level does not mean that physical function or long-term health improves.

Overdose Protocol

For a suspected overdose, contact a poison-information service or urgent medical care and provide the product, amount, time and other substances taken. Collapse, seizures or breathing difficulty require emergency help. Do not induce vomiting or attempt an antidote at home. Clinical treatment depends on symptoms and the substances involved.

Scientific & Technical Data

Pharmacodynamics

Ibutamoren stimulates the ghrelin receptor and promotes endogenous growth-hormone release, with downstream increases in IGF-1. It is a nonpeptide compound, distinct from injected growth hormone and from SARMs.

Pharmacokinetics

Ibutamoren is orally active. The duration of growth-hormone and IGF-1 changes is not the same measurement as plasma drug half-life. Trial pharmacology cannot establish the dose or bioequivalence of this particular tablet.

Storage and Handling

Keep tablets sealed in the original container, protected from excessive heat, moisture and accidental access. Use storage and expiry conditions supported by the finished preparation's stability information. A laboratory compound's storage temperature does not establish appropriate medicinal tablet storage. Arrange disposal through a pharmacy or supervising research service.

Product request

Enquire about Ibutamoren (MK 677)

Send a pricing, sample or distribution request. The product (Ibutamoren (MK 677) (25 mg/tab · 100 tabs)) is included automatically, and our team replies within one business day.